EML4-ALK在非小细胞肺癌中的表达及检测被引量：2

Detection and Expression of the Transforming EML4-ALK Fusion Gene in Non-small Cell Lung Cancer

下载PDF

导出

摘要非小细胞肺癌(NSCLC)为当今最常见的恶性肿瘤之一,近年来我国肺癌的发病率和病死率增长迅速,已居癌症相关死亡首位。分子靶向治疗已成为晚期NSCLC治疗的研究热点之一,靶向药物如何针对性地用于患者的治疗是关键。棘皮动物微管结合蛋白4(EML4)与间变淋巴瘤激酶(ALK)形成的融合基因主要表达于NSCLC中,这可能是与NSCLC表皮生长因子受体酪氨酸激酶抑制剂耐药相关的新靶点。 Non-small cell lung cancer（NSCLC） is one of the most common malignant tumors with rapidly increasing incidence and mortality,and has become the top cancer related death cause.Molecular target therapy has become one of the hot research points for treatments for late NSCLC,and the pertinent application of the target drug is the key of the treatment.Fusion genes of echinoderm microtubule associated protein like 4（EML4） and anaplastic lymphoma kinase（ALK） are mainly expressed in NSCLC,which is probably the new target related to resistance of NSCLC epidermal growth factor receptor to tyrosine kinase inhibitors.

作者梁宁单利王强

机构地区新疆医科大学附属肿瘤医院内一科

出处《医学综述》 2011年第19期2907-2910,共4页 Medical Recapitulate

关键词非小细胞肺癌棘皮动物微管相关蛋白样4-间变淋巴瘤激酶融合基因 Non-small cell lung cancer Echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase Fusion gene

分类号 R73 [医药卫生—肿瘤]

引文网络
相关文献

参考文献17

1Bean J,Brennan C,Shih J,et al.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J].P Natl Acad Sci U S A,2007,104(52):20932-20937.
2Han SW,Kim TY,Jeon YK,et al.Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation,K-ras mutation,and Akt phosphorylation[J].Clin Cancer Res,2006,12(8):2538-2544.
3Kwak EL,Camidge DR,Clark J,et al.Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor,PF-02341066[J].J Clin Oncol(Meeting Abstracts),2009,27(15 Suppl):3509.
4Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer[J].Nature,2007,448(7153):561-566.
5Lin E,Li L,Guan Y,et al.Exon array profiling detects EML4-ALK fusion in breast,colorectal,and non-small cell lung cancers[J].Mol Cancer Res,2009,7(9):1466-1476.
6Takeuchi K,Choi YL,Togashi Y,et al.KIF5B-ALK,a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer[J].Clin Cancer Res,2009,15(9):3143-3149.
7Soda M,Takada S,Takeuchi K,et al.A mouse model for EML4-ALK-positive lung cancer[J].Proc Natl Acad Sci U S A,2008,105(50):19893-19897.
8Inamura K,Takeuchi K,Togashi Y,et al.EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers[J].J Thorac Oncol,2008,3(1):13-17.
9Fukuyoshi Y,Inoue H,Kita Y,et al.EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers[J].Br J Cancer,2008,98(9):1536-1539.
10Kim KS,Jeong JY,Kim YC,et al.Predictors of the response to gefitinib in refractory non-small cell lung cancer[J].Clin Cancer Res,2005,11(6):2244-2251.